Key facts

Invented name
Mektovi
Active Substance
binimetinib
Therapeutic area
Oncology
Decision number
P/0037/2019
PIP number
EMEA-001454-PIP05-18
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of colorectal carcinoma
Route(s) of administration
Oral use
Contact for public enquiries

Pierre Fabre Médicament

Tel. +33 800326326
E-mail: medical_information@pierre-fabre.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

P/0037/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for binimetinib (Mektovi), (EMEA-001454-PIP05-18)

How useful do you find this page?